ARTICLE | Company News

GSK prices gene therapy Strimvelis

August 4, 2016 7:00 AM UTC

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) priced gene therapy Strimvelis ( GSK2696273) at EUR 594,000 ($663,679), spokesperson Anna Padula told BioCentury. In May, the European Commission approved Strimvelis to treat severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID) for whom no suitable HLA-matched related stem cell donor is available.

The Italian Medicines Agency (AIFA) agreed to reimburse for the treatment, Padula said. She added that the price compares favorably with long-term enzyme replacement therapy, which she said can cost EUR 3-EUR 4.2 million ($3.4- $4.7 million) over a 10-year period. ...